Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial

<p><b>Objective</b></p> Deucravacitinib, a tyrosine kinase 2 inhibitor, was assessed in a phase 2 trial in patients with active psoriatic arthritis (PsA). Here, we report effects of deucravacitinib from the patient perspective. <p><b>Methods</b></p> T...

書誌詳細
主要な著者:	Strand, V, Gossec, L, Coates, LC, Ogdie, A, Choi, J, Becker, B, Zhuo, J, Lehman, T, Nowak, M, Elegbe, A, Mease, PJ, Deodhar, A
フォーマット:	Journal article
言語:	English
出版事項:	Wiley 2024

類似資料

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
著者:: Kavanaugh, A, 等
出版事項: (2024)

Measuring outcomes in psoriatic arthritis
著者:: Ogdie, A, 等
出版事項: (2020)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
著者:: Ogdie, A, 等
出版事項: (2023)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
著者:: Helliwell, PS, 等
出版事項: (2022)

Psoriatic arthritis
著者:: FitzGerald, O, 等
出版事項: (2021)

Psoriatic arthritis: prospects for the future
著者:: Hackett, S, 等
出版事項: (2022)

Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
著者:: Ana Martins, 等
出版事項: (2023-05-01)

Classification and outcome measures for psoriatic arthritis
著者:: Leung, Y, 等
出版事項: (2018)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
著者:: Alexis Ogdie, 等
出版事項: (2023-05-01)

Is axial psoriatic arthritis the same as ankylosing spondylitis with psoriasis: a debate
著者:: Coates, LC, 等
出版事項: (2023)

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis
著者:: Leung, YY, 等
出版事項: (2020)

Methotrexate in psoriasis and psoriatic arthritis
著者:: Coates, L, 等
出版事項: (2020)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
著者:: Orbai, A-M, 等
出版事項: (2019)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
著者:: Strand, V, 等
出版事項: (2022)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
著者:: Tillett, W, 等
出版事項: (2017)

Hot topice debate: preventing psoriatic arthritis in patients with psoriasis
著者:: Vivekanantham, A, 等
出版事項: (2024)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
著者:: Coates, L, 等
出版事項: (2017)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
著者:: Gladman, DD, 等
出版事項: (2018)

Psoriatic arthritis: prospects for the future
著者:: Simon Hackett, 等
出版事項: (2022-03-01)

Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies
著者:: Mease, PJ, 等
出版事項: (2024)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
著者:: Philip J. Mease, 等
出版事項: (2024-01-01)

Sex-specific differences in patients with psoriatic arthritis: a systematic review
著者:: Coates, LC, 等
出版事項: (2022)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
著者:: Atul Deodhar, 等
出版事項: (2022-07-01)

Identification of psoriatic arthritis in patients with psoriasis
著者:: Coates, LC, 等
出版事項: (2023)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
著者:: Mease, PJ, 等
出版事項: (2020)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
著者:: Baraliakos, X, 等
出版事項: (2022)

Considerations for the definition of remission criteria in psoriatic arthritis
著者:: Mease, P, 等
出版事項: (2017)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
著者:: Weinstein, SM, 等
出版事項: (2021)

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group
著者:: Leung, Y-Y, 等
出版事項: (2023)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
著者:: Coates, L, 等
出版事項: (2020)

Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1 year results from two phase 3 studies
著者:: Gossec, L, 等
出版事項: (2024)

The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences
著者:: Coates, L, 等
出版事項: (2022)

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
著者:: de Vlam, K, 等
出版事項: (2018)

Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review
著者:: Leung, Y-Y, 等
出版事項: (2020)

Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free
著者:: Coates, LC, 等
出版事項: (2021)

Residual disease associated with suboptimal treatment response in patients with psoriatic arthritis: a systematic review of real world evidence
著者:: Coates, LC, 等
出版事項: (2022)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
著者:: Coates, LC, 等
出版事項: (2022)

Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis
著者:: Leung, YY, 等
出版事項: (2021)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
著者:: Coates, L, 等
出版事項: (2019)

Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis
著者:: Laure Gossec, 等
出版事項: (2024-02-01)